



FOCUS

Future of Care in Understanding Steatohepatitis


MASLD




**Concorde
El Salam Hotel**
Track location



7&8 | MAY | 2026
Add to your calendar



Registration
Tab to register



Organized by



EVA PHARMA



FOCUS - Middle East School of Steatotic Liver Disease (SLD)



We are pleased to invite you to participate in the **Middle East School of Steatotic Liver Disease**, a dedicated educational initiative focused on **MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)** and fatty liver disease.



Program Overview

This scientific program is designed to support hepatogastroenterologists across the Middle East, with the aim of addressing the increasing burden of liver diseases.

In **2026**, the curriculum will feature a comprehensive SLD module that integrates the latest global research, evolving disease nomenclature, and current best practices in diagnosis, management, and prevention.



Program Format

The training will be delivered across three structured waves, ensuring progressive learning and continuous engagement:

- 1 **Module 1:** Pathophysiology, Epidemiology & Diagnosis Foundations
- 2 **Module 2:** MASLD Risk Assessment & Therapeutic Interventions
- 3 **Module 3:** MASLD Cirrhosis, Multidisciplinary Care & Public Health Integration



Key Benefits for Participants

- Stay updated on the most common chronic liver disease worldwide (**MASLD**) whose prevalence continues to rise
- Gain hands-on knowledge to enhance your clinical practice
- Network with peers and regional & International experts in hepatology

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

UCHID ADVISORY BOARD



Gamal Esmat



Imam Waked



Maysaa Abdallah

COURSE CO-ORDINATORS



Ahmed Cordie



Faisal Abalkhail



Fatma Elrashdy



Sven Francque

ORGANIZING TEAM



Ibrahim Amer



Mahmoud hesham



Mohamed Abdallah



Sara Khaled



Youssef Khaled

7&8 | MAY | 2026

Organized by





FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

INTERNATIONAL SPEAKERS



Antonio Liguori



Emmanouil Tsochatzis



Mads Israelsen



Michael Pavlides



Mohammed Alsager



Stefano Romeo



Sven Francque

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

NATIONAL FACULTY



Ahmed Kamal



Aisha Sharkawy



Amr Abd El Monem



Ashraf Omar



Dina Esmael



Dina Omar



Engy El-Khateeb



Heba Abdallah



Ihab Salem



Khadiga Ali



Khaled Zalata



Maissa El Raziky



Medhat Elsahar



Mina Tharwat



Mohamed Imam



Yasmine Gaber

7&8 | MAY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

NUTRITION PANELISTS



Asmaa Essam



Dalia Shaaban



Hadeer Elmakrahy



Hala Mahmoud Saleh



Heba Abdel Malek



Mariam Ismail



Marwa Othman



Merna Marwan



Shadwa Ahmed Morsi

7&8 | MAY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

MENTORS & PANELISTS



Alaa Mohamed



Doaa Abdeltawab



Marwa Khalaf



Noura Gamal



Rania Elkafoury



Reham Reda



Salma Omran



Sara Hassan



Wael Soliman

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Time	Lecture	Speakers	Chairpersons
02:00 - 03:00 PM	Lunch		
03:00 - 03:30 PM	The new SLD nomenclature: Rationale and Criteria <hr/> Discussion	Sven Francque	
03:30 - 04:00 PM	The overlap between SLD and other liver diseases <hr/> Discussion	Mads Israelsen	Ashraf Omar Ihab Salem
04:00 - 04:30 PM	The epidemiology of SLD <hr/> Discussion	Mohammed Alsager	Maissa El Raziky
04:30 - 04:45 PM	Concepts behind SLD pathophysiology: The endocrinologist's perspective	Ihab Salem	Mina Tharwat Stefano Romeo
04:45 - 05:10 PM	Pathophysiology of SLD: The hepatologist's perspective <hr/> Discussion	Sven Francque	
05:10 - 05:30 PM	Factors interacting with MASLD	Mohamed Imam	
05:30 - 05:50 PM	Coffee Break		



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Time	Lecture	Speakers	Chairpersons
05:50 - 06:30 PM	Genetic predisposition of SLD Discussion	Stefano Romeo Ahmed Kamal	Emmanouil Tsochatzis
06:30 - 07:00 PM	Screening: What to screen for: get the terminology and context of use right Discussion	Emmanouil Tsochatzis	Ibrahim Amer Imam Waked
07:00 - 07:30 PM	Case discussion: Screening for liver fibrosis, Who and how to screen Discussion	Imam Waked	Maysaa Abdallah Mohamed Imam
07:30 - 08:00 PM	MR Elastography for the assessment of liver fibrosis Discussion	Michael Pavlides	Mohammed Alsager
08:00 - 09:00 PM	Dinner (Meet The Mentor)		



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Sven Francque

Prof. Sven Francque is a leading expert in gastroenterology and hepatology,

with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and portal hypertension as key expertise.

He earned his MD from the University of Antwerp and completed training in Belgium and France.

Prof. Francque received his PhD in 2011, focusing on vascular changes in steatosis.

He has authored over 300 papers and book chapters and served as an editor for JHep Reports. Currently, he is the chairman of the Department of Gastroenterology and Hepatology at the University Hospital Antwerp and a senior full professor at the University of Antwerp.

He is also a key figure in Belgian gastroenterology, coordinating national MASLD guidelines and the Belgian Week of Gastroenterology. He is member of the EASL Governing Board as educational councilor.

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis **MASLD**

Odense Liver Research Center, Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark



Mads Israelsen

Mads Israelsen, MD, PhD, is an Associate Professor at the Odense Liver Research Center, Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark. His research focuses on the overlap between metabolic dysfunction-driven and alcohol-driven liver disease, with particular emphasis on MetALD. He was principal investigator of the GALA-RIF trial, a randomised clinical study investigating rifaximin in patients with alcohol-related liver disease, published in *The Lancet Gastroenterology & Hepatology*.

Since the introduction of the steatotic liver disease nomenclature, he has worked to understand its clinical impact, including its effects on patient management and the design of clinical trials. He has a particular interest in the interplay between cardiometabolic and alcohol-related risk factors in SLD, aiming to improve identification, diagnosis, and treatment approaches for this growing patient population.

He is also a co-author of the *Lancet* Seminar on Steatotic Liver Disease, contributing to shaping the evolving global understanding of this disease spectrum.

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Mohammed Alsager

Dr. Mohammed Alsager is a Consultant Gastroenterologist and Transplant hepatologist

based at King Saud Medical City – Riyadh First Health Cluster. He earned his medical degree from King Abdulaziz University before completing advanced training in Internal Medicine, Gastroenterology, and Transplant Hepatology at Western University, Canada. He holds certification in Internal Medicine, Gastroenterology, Transplant Hepatology from Royal College of Physicians and Surgeons in Canada and American Board of Internal Medicine.

Dr. Alsager currently serves as the Program Director of Gastroenterology at Riyadh First Health Cluster, where he plays a key role in shaping training programs and advancing clinical services across the region.

His clinical and academic interests focus on liver transplantation, hepatocellular carcinoma (HCC), Autoimmune Hepatitis, and metabolic dysfunction–associated steatotic liver disease (MASLD), with a particular emphasis on developing and optimizing hepatology clinical care pathways and improving access to specialized liver care.

Dr. Alsager is actively involved in education, research, and healthcare system innovation, contributing to the advancement of hepatology practice and patient outcomes at both national and international levels.

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Stefano Romeo

Stefano Romeo, MD, PhD, is Professor of Clinical Diabetology and Senior Consultant in Endocrinology at Karolinska Institute and Karolinska University Hospital in Huddinge, Sweden. He is an internationally recognized leader in the human and molecular genetics of metabolic dysfunction-associated steatotic liver disease (MASLD), with major contributions that have helped define the genetic architecture of hepatic steatosis, steatohepatitis, fibrosis, and related cardiometabolic traits. His work has been central to identifying and characterizing key genetic determinants of liver fat accumulation and disease progression, and to clarifying how inherited variation influences the heterogeneity of MASLD across populations.

7&8 | MAY | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis **MASLD**

Professor Emmanouil Tsochatzis (MD, MSc, FEBTM, FRCP, PhD) is a Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London.

He is Head of the Centre for Metabolic Liver Disease in ILDH and a member of the Baveno steering committee for portal hypertension. His main research interests include non-alcoholic fatty liver disease, cirrhosis and portal hypertension and non-invasive assessment of liver fibrosis.

Professor Tsochatzis finished his specialty training and PhD in Hippokraton General Hospital in Greece, before moving to the Royal Free Hospital for his post-doc research under Professor Andy Burroughs. He is the recipient of the Rising Star in Gastroenterology prize by the UEG and the EASL Physician Scientist Fellowship.

His work on non-invasive fibrosis tests has informed the World Health Organization (WHO) guidelines on diagnosis and treatment of both HBV and HCV. He has designed and implemented a primary care pathway for NAFLD referrals to secondary care. He leads the specialist multidisciplinary service in NAFLD at the Royal Free Hospital and has an active research program. He has published more than 300 articles in peer-reviewed journals. He served a member of the EASL Governing Board from 2019 to 2022 and was the chair of the EASL Scientific Committee in 2021-22. He has received funding for his research from NIHR, EASL and EU Horizon 2020.



Emmanouil Tsochatzis

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

Professor Michael Pavlides is a Consultant Hepatologist and Associated Professor at Oxford University Hospitals since 2017.



Michael Pavlides

He graduated in Medicine in 2004 from The University College London.

Dr Pavlides has an interest in quantitative MRI and other non-invasive biomarkers for evaluation of liver disease.

He is the head of liver imaging at the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) and leads the hepato-biliary imaging work in the imaging theme of the Oxford NIHR Biomedical Research Centre. His research aims to develop and validate quantitative imaging biomarkers of liver and biliary disease.

His work focuses on the clinical application of MRI techniques for diagnosis of liver disease and its complication like portal hypertension.

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Time	Lecture	Speakers	Chairpersons
09:30 - 10:00 AM	Day 1 Recap	By: Mentors	
10:00 - 10:30 AM	Adiposopathy, "Sick fat" a way to unhealthy ageing & a world with unhealthy obesity!!	Amr Abd El Monem	
10:30 - 10:45 AM	Direct Blood biomarkers for assessment of liver fibrosis	Fatma Elrashdy	Dina Esmael
10:45 - 11:00 AM	Transient elastography for the assessment of liver fibrosis	Aisha Sharkawy	Engy El-Khateeb Medhat Elsahar
11:00 - 11:30 AM	Moderated Discussion: The art of handling non-invasive tools in the assessment of SLD	Emmanouil Tsochatzis	Mohamed Abdallah Sven Francque
11:30 - 12:00 PM	The role of the liver biopsy in the assessment of liver fibrosis Discussion	Dina Omar	
12:00 - 02:00 PM	Coffee Break & Prayer		
12:00 - 12:45 PM	Round Table Discussion with Nutrition Panelists		



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Time	Lecture	Speakers	Chairpersons
02:00 - 02:30 PM	Case discussion: Differentiated use of NITs for diagnosis of hepatic fibrosis among special groups (DM and/or obesity) <hr/> Discussion	Ahmed Cordie	Gamal Esmat
02:30 - 03:00 PM	Suggested Pathway for screening & diagnosis of liver fibrosis <hr/> Discussion	Emmanouil Tsochatzis	Ibrahim Amer Maysaa Abdallah
03:00 - 03:30 PM	Methods of assessment of hepatic steatosis	Heba Abdallah	Stefano Romeo Sven Francque
03:30 - 04:00 PM	Follow-up of SLD patients <hr/> Discussion	Antonio Liguori	
04:00 - 04:30 PM	Practical tips and tricks for using ultrasound in fatty liver disease	Yasmine Gaber	
04:30 - 05:30 PM	Workshop: Liver Biopsy Interpretation	Khaled Zalata Khadiga Ali	
05:30 - 06:00 PM	Lunch		



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

Dr. Antonio Liguori is a Consultant Hepatologist at Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Junior Lecturer at Università Cattolica del Sacro Cuore, Rome, Italy.



Antonio Liguori

He graduated in Medicine and Surgery and completed his specialty training in Internal Medicine and his PhD in Nutritional Sciences, Metabolism, Ageing and Gender-related Diseases at the same institution.

He performed a Hepatology Clinical and Research Fellowship at the Sheila Sherlock Liver Centre, Royal Free Hospital, University College London (2021–2022).

His clinical research focuses on the role of non-invasive assessment tools in diagnosis and follow up of MASLD and advanced chronic liver disease.

7&8 | **MAY** | 2026

Organized by



EVA PHARMA



 <p>GROUP 1</p>	<p>Mentor</p> <p>Rania Elkafoury</p>	<p>Name</p> <p>Alaa Hafez Elyamany Aya Awadelkarim Hanan Hamdy Mahmoud Fawzy Omar Ashraf Tasnim Farouk Adam</p>
 <p>GROUP 2</p>	<p>Mentor</p> <p>Alaa M. Mostafa</p>	<p>Name</p> <p>Amena Salem Bavly Ashraf Esraa Ibrahim Mariam Elsaadany Mostafa M. Elazab Nourhan Salah</p>
 <p>GROUP 3</p>	<p>Mentor</p> <p>Marwa Khalaf</p>	<p>Name</p> <p>Amr Rajeh Hussein Fatma Mahmoud Mahmoud Ahmed Manar Metwalli Rizk Marwan Ahmed Rawnaa Abdelaziz</p>



<p>GROUP 4</p>	<p>Mentor</p>	<p>Name</p>
	<p>Noura Gamal</p>	<p>Moataz Mobasher Mohamed Ahmed Samy Mohamed Nabil Rana Tarek Reem Elsharkawy Riham Hassan Mostafa</p>

<p>GROUP 5</p>	<p>Mentor</p>	<p>Name</p>
	<p>Sara Hassan</p>	<p>Amira Shaaban Soliman Gomaa Desouky Mohamed Sobhy Said Adel Mohammed Sara Sayed Saad</p>

<p>GROUP 6</p>	<p>Mentor</p>	<p>Name</p>
	<p>Reham Reda</p>	<p>Lina Saed Mansour Saad M. Elbayoumy Safaa Soliman Shaimaa Magdy Sherief Sholkamy Youssra Mohamed</p>